Corrigendum to "Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice" [J. Neuroimmunol. 210 (2009)22-29] (DOI:10.1016/j.jneuroim.2009.02.016);Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice

Journal of Neuroimmunology

Volumn 210, Issue 1-2, 2009, Pages 22-29

  Chen, Xiaohong ^a   Hu, Xueqiang ^a   Zou, Yan ^a   Pi, Rongbiao ^a   Liu, Mei ^a   Wang, Tieqiao ^a   Zheng, Xueping ^a   Liu, Meng ^a   Lin, Mingdong ^b   Liu, Peiqing ^a   Tao, Liang ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Experimental autoimmune encephalomyelitis; Minocycline; Multiple sclerosis; Prednisone

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; MINOCYCLINE; NERVE GROWTH FACTOR; PREDNISONE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; C57BL 6 MOUSE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DRUG COMBINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; INFLAMMATION; MONOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 67349273286     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.07.003     Document Type: Erratum

References (35)

1. Aloisi F. Growth factors. Neurol. Sci 24 (2003) S291-S294
2. Andersson P.B., and Goodkin D.E. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J. Neurol. Sci 160 (1998) 16-25
3. Beattie M.S., Harrington A.W., Lee R., Kim J.Y., Boyce S.L., Longo F.M., Bresnahan J.C., Hempstead B.L., and Yoon S.O. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 36 (2002) 375-386
4. Bergh F.T., Dayyani F., and Ziegler-Heitbrock L. Impact of type-I interferon on monocyte subsets and their differentiation to dendritic cells. J. Neuroimmunol 146 (2004) 176-188
5. Bjartmar C., Wujek J.R., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci 206 (2003) 165-171
6. Brundula V., Rewcastle B., Metz L., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a novel therapeutic for multiple sclerosis. Brain 125 (2002) 1297-1308
7. Brusaferri F., and Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J. Neurol 247 (2000) 435-442
8. Calza L., Giardino L., Pozza M., Micera A., and Aloe L. Time-course changes of nerve growth factor, corticotrophin-releasing hormone, and nitric oxide synthase isoforms and their possible role in the development of inflammatory response in experimental allergic encephalomyetis. Proc. Natl. Acad. Sci. U. S. A 94 (1997) 3368-3373
9. Cook L.L., Foster P.J., and Karlik S.J. Pathology-guided MR analysis of acute and chronic experimental allergic encephalomyelitis spinal cord lesions at 1.5 T. J. Magn. Reson. Imaging 22 (2005) 180-188
10. Diem R., Hobom M., Maier K., Weissert R., Storch M.K., Meyer R., and Bähr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J. Neurosci 23 (2003) 6993-7000
11. Diem R., Sättler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., and Bähr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128 (2005) 375-385
12. D'Intino G., Paradisi M., Fernandez M., Giuliani A., Aloe L., Giardino L., and Calza L. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3070-3075
13. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
14. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., and Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol 158 (2005) 213-221
15. Giuliani F., Fu S.A., Metz L.M., and Yong V.W. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J. Neuroimmunol 165 (2005) 83-91
16. Gold R. Combination therapies in multiple sclerosis. J. Neurol. 255 Suppl 1 (2008) 51-60
17. Hayashi M., Ueyama T., Nemoto K., Tamaki T., and Senba E. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J. Neurotrauma 17 (2000) 203-218
18. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis?. J. Neurol. Sci. 265 (2008) 93-96
19. Kerschensteiner M., Gallmeier E., Behrens L., Klinkert W.E.F., Kolbeck R., Hoppe E., et al. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role of inflammation?. J. Exp. Med. 189 (1999) 865-870
20. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., and Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53 (2003) 292-304
21. Kieseier B.C., Wiendl H., Hemmer B., and Hartung H.P. Treatment and treatment trials in multiple sclerosis. Curr. Opin. Neurol. 20 (2007) 286-293
22. Kuerten S., Kostova-Bales D.A., Frenzel L.P., Tigno J.T., Tary-Lehmann M., Angelov D.N., and Lehmann P.V. MP4-and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J. Neuroimmunol. 189 (2007) 31-40
23. Luccarini I., Ballerini C., Biagioli T., Biamonte F., Bellucci A., Rosi M.C., Grossi C., Massacesi L., and Casamenti F. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp. Neurol 211 (2008) 214-226
24. Noseworthy J.H. Progress in determining the causes and treatment of multiple sclerosis. Nature 399 (1999) A40-A47 (Suppl)
25. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
26. O'Neill E.J., Day M.J., and Wraith D.C. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J. Neuroimmunol 178 (2006) 1-8
27. Seukeran D.C., Eady E.A., and Cunliffe W.J. Benefit-risk assessment of acne therapies. Lancet 349 (1997) 1251-1252
28. Tselis A., Perumal J., Caon C., Hreha S., Chinga W., Din M., Stavern G.V., and Khan O. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur. J. Neurol. 15 (2008) 1163-1167
29. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., and Kapsenberg M.L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol 170 (2003) 4483-4488
30. Villoslada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S.W., Mobley W.C., Fisher S., and Genain C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system,. J. Exp. Med. 191 (2000) 1799-1806
31. Weinstock-Guttman B., Zivadinov R., Tamaño-Blanco M., Abdelrahman N., Badgett D., Durfee J., Hussein S., Feichter J., Patrick K., Benedict R., and Ramanathan M. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J. Neuroimmunol. 188 (2007) 167-174
32. Yong V.W., Wells J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 3 (2004) 744-751
33. Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C., Oh Y.J., Markelonis G.J., and Oh T.H. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci 27 29 (2007) 7751-7761
34. Zabad R.K., Metz L.M., Todoruk T.R., Zhang Y.J., Mitchell R., Yeung M., Patry D.G., Bell R.B., and Yong V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler. 13 (2007) 517-526
35. Zheng X.P., Hu X.Q., Zhou G.Y., Lu Z.Q., Qiu W., Bao J., and Dai Y.Q. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response. J. Neuroimmunol. 194 (2008) 107-114